Halobetasol propionate with tazarotene effective, safe for psoriasis
Halobetasol propionate plus tazarotene (HP/TAZ) significantly reduces the clinical severity of psoriasis with minimal adverse side effects, a recent study has shown.
The present analysis included data from two randomized, double-blind, multicentre, controlled phase 3 studies, where 418 psoriasis patients (65.1 percent male) were randomly assigned 2:1 to receive HP/TAZ lotion or vehicle control once daily for 8 weeks. The study outcomes included treatment success and safety.
At week 8, 35.8 percent (study 1) and 45.3 percent (study 2) of the participants who received HP/TAZ achieved the primary efficacy outcome of at least a 2-grade improvement in Investigator’s Global Assessment score from baseline. This was significantly higher than in the vehicle control groups (7.0 and 12.5 percent, respectively; p<0.001 for both).
Similarly, at the same time point in study 1 and study 2, significantly more participants in the HP/TAZ vs vehicle control group showed improvements in erythema (44.2 percent and 49.6 percent vs 10.0 percent and 18.7 percent) and plaque elevation (59.3 percent and 59.7 percent vs 17.9 percent and 21.3 percent; p<0.001 for all).
In terms of safety, adverse events were more common in participants who received the HP/TAZ lotion than in those who received the control (35.9 percent vs 21.4 percent). Majority of the adverse events (AEs) were mild or moderate in severity (85.6 percent); only three serious AEs were reported, none of which were related to the HP/TAZ lotion,
The most common treatment-related AEs were contact dermatitis, pruritus and pain the application site.